[Effects of a chlormadinone acetate-containing ovulation inhibitor on androgenization pictures and liver and lipid metabolism in young females].

Twenty-two patients, average age 22 years, were treated for androgenization phenomena with a combination preparation containing ethinyl estradiol and chlormadinone acetate (Neo-Eunomin) over a period lasting 12 cycles. Under this therapy acne, seborrhea, alopecia and hirsutism improved. The hepatic metabolism parameters checked before and during the study (alkalic phosphatase, SGPT, gamma-GT and total bilirubin) showed no pathologic changes and decreased significantly toward the end of the treatment period. SGOT remained uninfluenced. The effects on the lipoproteins checked were favorable, as the atherogenic index (LDL/HDL) dropped from 2.2 prior to therapy to 1.7 in the twelfth cycle of the treatment period. The HDL fraction increased significantly in the very first cycle, while the LDL fraction remained almost constant. There was a significant increase in cholesterol and triglycerides. The serum androgen count (testosterone and DHEA-S) was significantly lowered. There was a clear decrease in testosterone in saliva.